Last reviewed · How we verify
Aprepitant Injection
At a glance
| Generic name | Aprepitant Injection |
|---|---|
| Also known as | dexamethasone, ondansetron, Emend |
| Sponsor | Qilu Pharmaceutical (Hainan) Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) (PHASE2)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (PHASE3)
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (PHASE3)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (PHASE4)
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |